Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. 4D Molecular Therapeutics ( (FDMT)) has ...

4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer doesn’t recommend buying more AppLovin Corporation (NASDAQ:APP) stock. “Let's take a little off the table just to be prudent,” Cramer added.

Bubsy 4D is a colorful and expressive 3D platformer that blends nostalgic charm with modern movement mechanics - and a furmidable sense of humor. In Bubsy 4D, the Woolies - an aggressive, ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.63 per share a year ago.

Copilot 3D can convert 2D images into 3D models that can be used in design tools. Copilot 3D can convert 2D images into 3D models that can be used in design tools. is a senior editor and author of ...

Please provide your email address to receive an email when new articles are posted on . This activity is supported by independent medical education grants from 4D Molecular Therapeutics; AbbVie Inc.; ...